Pharmaceutical Technology

JULY 5, 2022

On leaving the liver cells, the virus hijacks bits of cell membrane and conceals itself from antibodies that would have isolated the virus before it travelled far through the bloodstream. In addition, the scientists later found that the HAV needs TENT4A/B for its replication.

Protein 130

Protein RNA Genome Genomics 130

pharmaphorum

JANUARY 20, 2021

Laboratory studies have confirmed that antibodies stimulated by Pfizer and BioNTech’s COVID-19 vaccine can neutralise the new, more transmissible variant of SARS-CoV-2 identified in the UK. VOC 202012/01 has an unusually high number of genetic changes however, with 10 mutations affecting the spike protein. lineage or VOC 202012/01.

Vaccination 98

Vaccination Vaccine Antibody Protein 98

The Pharma Data

AUGUST 28, 2020

While we know for sure that children can catch the virus, Prof Viner says data from antibody blood tests suggest they may be less susceptible to catching it than adults – particularly children under the age of 12. Do they pass it on to others? ” So can we draw a conclusion?

Scientist 52

Scientist Genetics Antibody Development 52

pharmaphorum

MARCH 28, 2022

Israel-based AION Labs and German independent research institute BioMed X announced its third global call for applications to form a new start-up company focused on using AI to design and optimise antibodies for targeted therapies. . From there, they evaluate what kind of antibodies are produced. ” The Application .

Pharma Companies 98

Pharma Companies Antibody Protein Development 98

The Pharma Data

DECEMBER 16, 2020

Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories.

Genetics 52

Genetics Antibody FDA Approval Medicine 52

The Pharma Data

DECEMBER 17, 2020

NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. , 17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc.

Antibody 52

Antibody Medicine Production Trials 52

The Pharma Data

JANUARY 19, 2021

Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories.

Genetics 52

Genetics Antibody FDA Approval Medicine 52

The Pharma Data

NOVEMBER 30, 2020

Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories.

Genetics 52

Genetics Antibody FDA Approval Medicine 52

The Pharma Data

OCTOBER 27, 2020

Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories.

Genetics 52

Genetics Antibody FDA Approval Medicine 52

The Pharma Data

AUGUST 18, 2020

REGN-COV2 is Regeneron’s two-antibody combination currently in late-stage clinical trials for the treatment and prevention of COVID-19 infection. About REGN-COV2 REGN-COV2 was designed specifically by Regeneron scientists to block infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron will distribute REGN-COV2 in the U.S.

Antibody 52

Antibody Clinical Trials Clinical Trials Manufacturing 52

pharmaphorum

OCTOBER 31, 2022

s Inmazeb (consisting of the monoclonal antibodies atoltivimab, maftivimab, and odesivimab-ebgn). Indeed, Regeneron believes that the success with Ebola could potentially have ushered in “a new era in which monoclonal antibodies could be used to fight viral diseases and global pandemics.”.

Production 52

Production FDA Approval Antibody Gene 52

The Pharma Data

OCTOBER 28, 2020

NASDAQ: REGN) today announced positive, prospective results from an ongoing Phase 2/3 seamless trial in the COVID-19 outpatient setting showing its investigational antibody cocktail, REGN-COV2, met the primary and key secondary endpoints. Regeneron Pharmaceuticals, Inc. Yancopoulos , M.D., President and Chief Scientific Officer of Regeneron.

Antibody 40

Antibody Trials Production Clinical Trials 40

Scienmag

FEBRUARY 22, 2021

Monoclonal antibodies are part of the therapeutic arsenal for eliminating cancer cells. ” But how do these antibodies function within the tumor? Using innovative in vivo imaging approaches, scientists […]. Using innovative in vivo imaging approaches, scientists […].

In-Vivo 41

In-Vivo Antibody Scientist Allergies 41

The Pharma Data

JULY 6, 2021

GlaxoSmithKline plc (LSE/NYSE: GSK) and Alector (Nasdaq: ALEC), today announced a strategic global collaboration for the development and commercialisation of two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101) designed to elevate progranulin (PGRN) levels. ” Arnon Rosenthal, Ph.D.,

Genetics 52

Genetics Gene Antibody Development 52

The Pharma Data

DECEMBER 5, 2020

NASDAQ: REGN) today announced updated data for REGN5458, a BCMAxCD3 bispecific antibody, from the Phase 1 portion of a Phase 1/2 trial in patients with relapsed or refractory (R/R) multiple myeloma. These allow for the creation of bispecific antibodies that closely resemble natural human antibodies with no linkers or artificial sequences.

Antibody 40

Antibody Production Trials Medicine 40

FDA Law Blog

DECEMBER 7, 2022

In simple terms from a non-scientist, these gene therapies add functional versions of genes to patients that do not have them, and thus the idea is to have these genes function in the same way as they do in individuals without these disorders. This product was developed by uniQure prior to being licensed to CSL Behring.

Gene Therapy 119

Gene Therapy Gene FDA Approval Production 119

pharmaphorum

AUGUST 13, 2020

The FDA has started a speedy review of Regeneron’s ANGPTL3-targeting antibody evinacumab for a rare, inherited disorder that dramatically raises the risk of heart disease. There’s no data showing that the drug can reduce progression to heart disease yet, but it’s widely believed that cutting blood lipids can reduce that risk.

Drugs 52

Drugs Antibody Sales Cardiology 52

The Pharma Data

OCTOBER 30, 2020

NASDAQ: REGN) received today a recommendation from the independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19 that the current hospitalized patient trial be modified. TARRYTOWN, N.Y. , Regeneron Pharmaceuticals, Inc.

Production 52

Production Antibody Manufacturing Trials 52

The Pharma Data

APRIL 8, 2021

In addition to testing THOR-707 in combination with KEYTRUDA, Sanofi is planning to evaluate the activity of this novel biologic in combination with other anti-PD-1 antibodies, including Libtayo ® 1 , (cemiplimab) anti-CD38 antibody Sarclisa ® (isatuximab) and anti-EGFR. Kenilworth, NJ, USA (known as MSD outside the U.S.

Immune Response 52

Immune Response Engineer Antibody Genetics 52

XTalks

FEBRUARY 24, 2023

Lunsumio is a CD20xCD3 T-cell engaging bispecific antibody that works by targeting the protein CD20 on the surface of B cells and CD3 on the surface of T cells. Dr. Laport: Lunsumio (mosunetuzumab-axgb) is the first CD20xCD3 T-cell engaging bispecific antibody approved by the FDA.

Drugs 52

Drugs FDA Approval Antibody Medicine 52

The Pharma Data

MARCH 4, 2021

Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. Detailed results from this Phase 3 trial will be published later this year. Source link:[link].

Genetics 52

Genetics Medicine Antibody Trials 52

The Pharma Data

SEPTEMBER 15, 2020

” BigHat Biosciences: BigHat Biosciences is an early-stage Bay Area startup reimagining antibody discovery and engineering to create better antibodies faster and undertake novel designs far beyond what’s possible today. About MBC BioLabs MBC BioLabs is dedicated to helping life-science startups succeed.

Life Science 52

Life Science Protein Antibody Scientist 52

The Pharma Data

JUNE 26, 2021

Libtayo is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T-cells. The primary efficacy endpoint was confirmed ORR, and a key secondary endpoint was DOR, assessed by independent central review. About Libtayo. Source link: [link].

Genetics 52

Genetics Antibody Trials Medicine 52

The Pharma Data

OCTOBER 18, 2021

Northwestern Medicine scientists have shown for the first time that coronavirus vaccines and prior coronavirus infections can provide broad immunity against other, similar coronaviruses. “We found that these individuals developed antibody responses that neutralized a common cold coronavirus, HCoV-OC43,” Penaloza-MacMaster said.

Vaccination 40

Vaccination Vaccine Immune Response Antibody 40

Delveinsight

AUGUST 20, 2020

Now, the scientists at the Salk Institute have found a potential solution to those problems. The team successfully protected HILOs from the immune system without genetic manipulation. The takeover will proffer J&J control of an anti-FcRn antibody, which completed a phase 2 trial in myasthenia gravis earlier this year.

Gene Therapy 52

Gene Therapy Research Gene Antibody 52

Delveinsight

FEBRUARY 11, 2021

Immune-stimulating antibodies, which target the receptor CD40, are emerging as promising therapies for pancreatic cancer. The scientists analyzed samples from patients with the most common pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC). Enhancing the response to immuno-oncology in pancreatic cancer.

Gene Therapy 52

Gene Therapy Gene Immune Response In-Vivo 52

Scienmag

APRIL 16, 2021

Gothenburg, Sweden, April 16th, 2021 Oblique Therapeutics AB, a Sweden-based biotech company, in collaboration with Karolinska Institutet (Stockholm, Sweden), Gothenburg University (Sweden) and several local biotechs published promising research results Science Advances publishes proteomics technology from Oblique Therapeutics AB with a potential to (..)

Antibody 40

Antibody Medicine Research Scientist 40

The Pharma Data

JANUARY 13, 2021

The new vaccine is made up of a deactivated cold virus into which scientists cut-and-paste a genetic version of the “spike” protein used by the coronavirus to infect cells. More than 90% of participants mounted an immune response within a month, and all had levels of neutralizing antibodies by day 57.

Vaccination 40

Vaccination Vaccine Trials Immune Response 40

The Pharma Data

AUGUST 30, 2021

Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways. It is not an immunosuppressant and does not require lab monitoring. Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.

Trials 52

Trials Medicine Genetics Antibody 52

The Pharma Data

JUNE 18, 2023

” Emgality is a monoclonal antibody (mAb) that inhibits the effects of CGRP by binding directly to CGRP, while gepants like Nurtec ODT bind to and block the CGRP receptor. Emgality is administered via injection, and Nurtec ODT is administered orally.

Clinical Trials 40

Clinical Trials Clinical Trials Trials Medicine 40

The Pharma Data

JULY 6, 2021

But HIV’s ability to mutate isn’t unique among RNA viruses – most viruses develop mutations, or changes in their genetic code, over time. They compared these sequences with the original SARS-CoV-2 genome, cross-checking the genetic changes against their highly networked epitopes. 1.351 Beta, P1 Gamma, and B.1.617.2

Vaccination 52

Vaccination Vaccine Research Immune Response 52

The Pharma Data

JUNE 7, 2022

1-2 Lebrikizumab is a novel, monoclonal antibody (mAb) that binds to the interleukin-13 (IL-13) protein with high affinity to specifically prevent the formation of IL-13R?1/IL-4R? Lebrikizumab is a novel, investigational, monoclonal antibody designed to bind IL-13 with high affinity to specifically prevent the formation of the IL-13R?1/IL-4R?

Trials 40

Trials Clinical Trials Clinical Trials Medicine 40

The Pharma Data

NOVEMBER 6, 2020

Scientists believe a combination of genetic predisposing factors and the environment causes JIA but the exact cause is unknown. Juvenile idiopathic arthritis (JIA) is a condition involving joint inflammation that lasts more than six weeks in children or adolescents under 16 years of age.

Nurses 52

Nurses Research Genetics Antibody 52

Intouch Solutions

SEPTEMBER 27, 2024

With the theme “Shaping the Future of Anticancer Therapies,” ESMO 2024 saw record crowds and focused on advancements across immuno-oncology, antibody drug conjugates (ADCs) and numerous malignancies. We heard about monoclonal antibodies, bispecifics and antibody-drug conjugates, and many of these are being used in combination.

DNA 59

DNA Trials Antibody Marketing 59

Pharmaceutical Technology

FEBRUARY 3, 2023

With scientists fervently developing mRNA vaccines, nucleic acid therapeutics, and viral vector-based gene therapies, clinicians are set to have a growing number of tools available to treat a wide range of conditions, from infectious diseases to genetic disorders and more. The field of genomic medicine has reached a true turning point.

Genomics 244

Genomics Genome Medicine Gene Therapy 244

The Pharma Data

JANUARY 12, 2021

million additional doses of the casirivimab and imdevimab antibody cocktail, bringing total potential U.S. Under the new agreement, the government will purchase all finished doses of the casirivimab and imdevimab antibody cocktail delivered by June 30, 2021 , up to 1.25 TARRYTOWN, N.Y. , 12, 2021 /PRNewswire/ — . million doses.

Antibody 52

Antibody Production Manufacturing Clinical Trials 52

Delveinsight

DECEMBER 3, 2020

Roche receives FDA authorization for the quantitative COVID-19 antibody test. Roche has got an authorization from the FDA for a more accurate COVID-19 blood test capable of measuring the levels of specific antibodies, which target the cell-unlocking spike protein of coronavirus. Reversing vision loss by rolling back the ageing clock.

Gene Therapy 52

Gene Therapy Gene Antibody Research 52